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ABSTRACT
Sialic acids, existing as terminal sugars of glycoconjugates, play important roles in various physiological and path
ological processes, such as cell-cell adhesion, immune defense, tumor cell metastasis, and inflammation.
Sialyltransferases (STs) catalyze the transfer of sialic acid residues to non-reducing oligosaccharide chains of proteins and lipids, using cytidine monophosphate N-acetylneuraminic acid (CMP-Neu5Ac) as the donor. Elevated
sialyltransferase activity leads to overexpression of cell surface sialic acids and contributes to many disease developments, such as cancer and inflammation. Therefore, sialyltransferases are considered as potential drug targets
for disease treatment. Inhibitors of sialyltransferases thus are of medicinal interest, especially for the cancer
therapy. In addition, sialyltransferase inhibitors are useful tool to study sialyltransferase function and related
mechanisms. This review highlights recent development of inhibitors of sialyltransferases reported since 2004.
The inhibitors are summarized as eight groups: 1) sialic acid analogs, 2) CMP-sialic acid analogs, 3) cytidine
analogs, 4) oligosaccharide derivatives, 5) aromatic compounds, 6) flavonoids, 7) lithocholic acid analogs, and
8) others. This article is part of a Special Issue entitled: Physiological Enzymology and Protein Functions.

1. Introduction

Sialic acids (SAs), a family of 9-carbon containing acidic monosaccharides, often terminate the glycan structures of cell surface and
secreted glycoconjugates such as glycoproteins and glycolipids. They
are found on both N- and O-linked glycans, being attached to either
galactose (Gal) and N-acetylgalactosamine (GalNAc) units via α2,3- or
α2,6-linkages, or to SA via α2,8- or α2,9-linkages, whose syntheses
are catalyzed by specific enzymes (Fig. 1) [1 ]. In addition, various substituents present on carbon 4-, 5-, 7-, 8- and 9-positions generating
more than 50 SA species. Their C-2 quaternary carbon center with one
carboxylate group and two oxygen substitutions makes them unique
from other common sugars. The C-5-amino derivative represents the
well-known neuraminic acid, and its amino functional group can be
either acetylated (N-acetylneuraminic acid, Neu5Ac) or glycolylated
(N-glycolylneuraminic acid Neu5Gc). KDN (3-deoxy-D-glycero-Dgalacto-non-2-ulopyranosonic acid), a sialic acid without amino
functionality at C-5 position, is also found in human beings. The most
abundant sialic acid is Neu5Ac.
Given their terminal location on glycans and their hydrophilic and
electronegative features, sialic acids (N-acetylneuraminic acid) play
very important roles in regulating cellular interactions with ligands,
microbes and neighboring cells and in controlling cellular activation, dif-

ferentiation, transformation and migration [2,3]. The levels and linkages
of sialic acids named as sialylation status vary upon cell activation related to both physiological and pathological processes [4]. Changes in
sialylation of cell surface modulate cellular activity as well [5]. Therefore,
cell surface sialic acids are considered as very important molecules in
regulating many physiologically and pathologically important processes.
In eukaryotic cells, Neu5Ac is synthesized in the cytosol and then
is transferred to nucleus and activated by cytosine 5'-monophosphate
N-acetylneuraminic acid (CMP-Neu5Ac) synthetase to form CMPNeu5Ac that then goes to Golgi to be transferred to glycoconjugates by
sialyltransferases, which are subsequently secreted or delivered to cell
surface (Fig. 2). So far, twenty sialyltransferases have been identified
for catalyzing the addition of sialic acids to terminal non-reducing position of the oligosaccharides of different sugar acceptors in different linkages on proteins and lipids (Table 1) [5-7]. Sialyltransferases normally
locate at the Golgi apparatus as integral membrane proteins adding
sialic acids to glycoconjugates during their syntheses. In addition,
some sialyltransferases are also expressed as soluble enzymes [8]
and sialyltransferases activity at plasma membrane are also reported
in immune cells [9]. Each sialyltransferase presents high selectivity toward its acceptor substrate and create α2,3-, α2,6-, and α2,8-linkages,
respectively. Sialyltransferases can be organized in four families depending on their linkage specificities and acceptor substrates: (i) the
ST3Gal family, catalyzing the addition of sialic acid to a terminal galactose of N-,O-linked glycans and glycolipids in α2,3-linkage; (ii) the
ST6Gal family, adding ct2,6-linking sialic acid to galactose residues
of N-glycans; (iii) the ST6GalNAc family, adding sialic acid to terminal

N-acetylgalactosamine (GalNAc) residues of glycoproteins and glycolipids, in α2,6-linkage; and finally, (iv) the ST8Sia family, the only
known sialyltransferases promoting the linkage to another sialic acid
residue in N- or O-glycans, in ct2,8-linkage (Table 1). Overall, the levels
and linkages of sialic acids named as sialylation status are controlled
by the levels and activities of sialyltransferases, which vary upon cell
activation related to both physiological and pathological processes.
2. Hypersialylation and sialyltransferase inhibition
The level of cell surface sialic acid expression is highly related to
many pathological processes. For example, cancer cells express high
density of sialic acids known as hypersialylation that contributes to cancer cell progression and metastasis. The high expression of sialic acids
can protect cancer cells from apoptosis, promote metastasis, and has
been suggested to confer resistance to therapy [10-13]. Overexpression
of sialyltransferases and other glycosyltransferases during malignant
transformation and progression results in aberrant sialylation of cancer
cells [14-16]. Therefore, interfering hypersialylation may provide a
practical approach in cancer therapy and thus the overexpressed
sialyltransferases are potential drug targets. In addition, it has been
found that overexpression of polysialic acids is related to cancer
progression and metastasis recently. Therefore, polysialyltransferases
have been considered as an attractive anti-cancer target as well.
Sialylation donor (CMP-Neu5Ac), acceptor, and the transition
state are involved in the sialic acid transfer process catalyzed by the
sialyltransferases. Therefore, analogs of CMP-Neu5Ac, acceptor, and
the transition state were proposed toward the development of
sialyltransferase inhibitors. The early developments on sialyltransferase
inhibitors were well summarized in comprehensive review papers
in 2003 [17,18]. Since then, tremendous investigations have been
conducted for exploring effective sialyltransferase inhibitors, especially,
for anticancer agent development. In addition, novel sialyltransferase
inhibitors from natural product screening showed promising
results. This review highlights the inhibitors of sialyltransferase and
polysialyltransferase reported since 2004, with variety of structures
and with both in vitro and in vivo activities. The inhibitors are summarized as eight groups: 1) sialic acid analogs, 2) CMP-sialic acid analogs,

3) cytidine analogs, 4) oligosaccharides derivatives, 5) aromatic com
pounds, 6) flavonoids, 7) lithocholic acid analogs, and 8) others.

2. J. Sialic acid analogs
Most glycosyl transfer reactions proceed through a flattened halfchair conformation with a substantial oxocarbenium-ion character
[19]. Therefore, sugar donor analogs and transition-state analogs
can be used as potent inhibitors of glycosyltransferases. Fluorinated
sialic acid analog was identified as transition state inhibitor of
sialyltransferases earlier [20]. However, its high hydrophilic property
prevents it from efficiently crossing cell membranes and thus its potential utility in vivo. Paulson and co-workers reported peracetylated analogs of sialic acid bearing a fluorine atom proximal to the endocyclic
oxygen (P-3Fax-Neu5Ac, 1, Fig. 3) as a cell-permeable specific inhibitor
of the sialyltransferases [21,22]. This is an elegant approach by taking
advantage of the relaxed substrate specificity of enzymes in the sialic
acid salvage pathways and its ability to accommodate unnatural analogs
of sialic acid. Their results showed that P-3Fax-Neu5Ac was readily converted to the corresponding donor substrate analog intracellularly. This
intermediate then effectively shuts down the synthesis of a spectrum of
sialylated glycan epitopes and remodels the cell-surface glycome within
days. Further, they confirmed that the inhibitor alone or in combination
with peracetylated analogs of fucose substantially inhibits the formation
of the sialylated and fucosylated tetrasaccharide sialyl Lewis X (SLex) in
a human myeloid cell line (HL-60 cells), abrogating its interaction with
E- and P-selectins, which recruit effector cells to inflammatory sites.
Most recently, they reported their further in vivo study results that
P-3Fax-Neu5Ac acts as a global sialyltransferase inhibitor in mice
and causes the kidney and liver dysfunction. Administering P-3FaxNeu5Ac to mice dramatically decreases sialylated glycans in cells of all
tissues tested, including the blood, spleen, liver, brain, lung, heart, kidney, and testes. These results confirmed a critical role for sialosides in
the liver and kidney function and documented the feasibility of pharmacological inhibition of sialyltransferases for in vivo modulation of
sialoside expression. These studies paved the way for using sialic acid
analog inhibitors to explore the roles of sialylated glycans in biology
and mechanisms of disease and opened the possibility of using sialic

Fig. 2. Sialyltransferases catalyzed transfer of sialic acid to a suitable glycan by using CMP-sialic acid.

cancer therapy and infection and inflammation diseases. Its further
preclinical testing is anticipated.

Table 1

Human sialyltransferases.
Modified from Refs [5-7].

Sialyltransferase

Preferred acceptor saccharide

Glycan specificity

ST3Gal-I
ST3Gal-ll
ST3Gal-III
ST3Gal-lV
ST3Gal-V
ST3Gal-VI
ST6Gal-I
ST6Gal-II
ST6GalNAc-l

Gal|31,3GalNAc
Galβ1,3GalNAc
Galβ1,3(4)GlcNAc
Galβ,4(3)GlcNAc
Galβ1 ,4Glc-ceramide
Galβ1,4GlcNAc
Galβ1,4GlcNAc
Galβ1,4GlcNAc
GalβNAcα1, O-Ser/Thr
Galβ1,3GalNAcαl, O-Ser/Thr
Galβ1,3GalNAcal, O-Ser/Thr
Siaα2,3Galβ1,3GalNAc
Siaα2,3Galβ1,3GalNAc
GMlb
All α-series gangliosides
Siaa2,3Galβ1,4Glc-ceramide
Siaα2,3Galβ1,4GlcNAc
Siaα2,3Galβ1,4GlcNAc
(Siaα2,8)nSiaα2,3Galβ1-R
GM1b.GT1b, GD1a, GD3
Siaα2,3(6)Gal

O-glycan
O-glycan
O-glycan, N-glycan
N-glycan, O-glycan
Glycolipid
N-glycan, glycolipid
N-glycan
N-glycan
O-glycan

ST6GalNAc-ll
ST6GalNAc-lll
ST6GalNAc-lV
ST6GalNAc-V
ST6GalNAc-VI
ST8Sia-I
ST8Sia-II
ST8Sia-III
ST8Sia-IV
ST8Sia-V
ST8Sia-VI

O-glycans
O-glycan
O-glycan
Glycolipid
Glycolipid
Glycolipid
N-glycan on NCAMa
N-glycan on NCAM
N-glycan on NCAM
Glycolipid
Sialic acid on O-glycan

a NCAM: Neural cell adhesion molecule.

acid analog as drug for disease with highly expressed sialic acids and
sialyltransferases.
Recently, Edma and co-workers reported the potential of P-3FaxNeu5Ac to block the synthesis of sialoglycans in murine melanoma
cells and the consequences on cell adhesion, migration, and in vivo
growth [23]. Their results showed that P-3Fax-Neu5Ac readily causes
depletion of α2,3-/ct2,6-linked sialic acids in B16F10 cells for several
days. Even long-term inhibition of sialylation for 28 days was feasible
without affecting cell viability or proliferation. Moreover, P-3FaxNeu5Ac proved to be a highly potent inhibitor of sialylation even at
high concentrations of competing sialyltransferase substrates. Further,
P-3Fax-Neu5Ac-treated cancer cells exhibited impaired binding to
poly-L-lysine, type I collagen, and fibronectin and diminished migratory
capacity. Finally, blocking sialylation of B16F10 tumor cells with this
sialic acid analog reduced their growth in vivo. These results indicated
that P-3Fax-Neu5Ac is a potent glycomimetic capable of inhibiting aberrant sialylation that can potentially be used for anticancer therapy. In general, sialylation is a necessary process in all cells, thus sialyltransferase
inhibitors may affect physiological important sialylation as well. In
order to avoid disrupting the physiologically important processes, the
site specific approaches are much needed related to its therapeutic efficiency. Most recently, this group reported an enhanced pharmacokinetic
approach by formulation of P-3Fax-Neu5Ac into poly(lactic-co-glycolic
acid) nanoparticles coated with antityrosinase-related protein-1
antibodies for targeted delivery of P-3Fax-Neu5Ac into cancer cells [24].
They showed that an intravenous injection of melanoma-targeting
P-3Fax-Neu5Ac nanoparticles prevents metastasis formation in a murine
lung metastasis model. This targeting strategy to interfere with sialic aciddependent processes at the pathological sites is expected to be useful for

Fig. 3. Sialic acid analog inhibitor of sialyltransferases. 1, Inhibition of enzyme: α2,3-/α2,6-

ST, Refs: [21-24].

2.2. CMP-sialic acid analogs
CMP-sialic acid is synthesized in the nucleus and then transported
into the lumen of the Golgi apparatus via a CMP-sialic acid transporter,
where sialyltransferase catalyzes the transfer of the sialic acid moiety to
glycans attached to ceramides and glycoproteins (Fig. 2) [7]. Analogs of
the nucleotide sugar donor substrates have been identified as potent
inhibitors with selective and broad inhibition properties for glycosyltransferases. Therefore, CMP-sialic acid analogs have also been reported
as potent inhibitors of sialyltransferases [17,18]. On the other hand, by
taking both the donor's high affinity and acceptor's high selectivity,
bisubstrate analogs, in which donor and acceptor analogs are covalently
attached to each other, have also been proposed and confirmed as potent and selective inhibitors of sialyltransferases. Izumi et al. reported
a bisubstrate analog containing the donor substrate (CMP-Neu5Ac)
mimic and the acceptor substrate (galactose) and partial structure of
the bisubstrate analog containing an ethylene group in place of the exocyclic anomeric oxygen of CMP-Neu5Ac (2-6) (Table 2) [25]. Among
these bisubstrate analogs, cytidin-5'-yl sialylethylphosphonate (2)
showed the highest inhibiting activity against rat recombinant α2,3and α2,6-ST (IC50 = 0.047,0.34 mM).
It is still unclear about the specific binding sites of sialyltransferases
for the donor CMP-Neu5Ac. But the modification of Neu5Ac of
CMP-Neu5Ac for seeking effective sialyltransferase inhibitors is worth
exploring . Hosoguchi and co-workers reported that modification at
C-5 position of CMP-Neu5Ac with bulky steroid analog (7) had strong
impact to the catalytic action by sialyltransferases [26]. It showed that
compound 7 is a highly promising inhibitor against ct2,3-ST (ST3Gal
111) (1C5O = 8.2 pM). Considering that many inhibitors inspired from
transition-state analogs during glycosylation catalyzed by α2,3-/ct2,6STs showed much higher inhibitory effects on ct2,6-STs rather than
α2,3-STs [18], these results suggested that the donor binding site of
α2,6-STs might be quite different from those of α2,3-STs, although
both ct2,3/α2,6-STs share a natural CMP-Neu5Ac as a redundant
donor substrate. In another study, C-5 position modified CMP-sialic
acid analog carrying a fluorine atom at C-3 of sialic acid moiety was reported by Kanie and Ito [27]. The CMP-5"-fluorescently labeled 3"-F-Sia
derivative (8) (Table 2) was accepted by CMP-sialic acid transporter
and exhibited high inhibitory activity against STs (Ki = 31.7 mM).
These two researches above suggested that modifications at C-5
position of Neu5Ac without loss of an original amide linkage and C-3
position with small fluorine allow for ideal molecular design and
further optimization study of highly selective inhibitors against various
sialyltransferases.
It is a concern that charged phosphate linkage in CMP-Neu5Ac may
impart poor cellular permeability and is prone to phosphatase activity
resulting in a significant or total loss of activity. To address whether
non-charged CMP-Neu5Ac can be effective competitive inhibitors to
sialyltransferase, Zou and Jennings designed a library of CMP-Neu5Ac
analogs with a non-charged linkers replaced with a nonionic triazole
moiety (compounds 9,10) (Table 2) [28]. These mimics still contain
both the sialic acid and cytidine residues responsible for binding to
the sialyltransferase active site. In addition, instead of sialic acid, a
2-deoxy-2,3-dehydroacetylneuraminyl moiety was connected to
cytidine by a triazole or a sulfamide linkage as CMP-Neu5Ac analogs
(compounds 11-17) (Table 2). They expected that this might help to
achieve trigonal planarity at the anomeric center of the transition
state involved during glycosylation, while also by slightly increasing
hydrophobicity. Further, compounds lack both sialic acid and a phosphodiester linkage that were replaced, respectively, by an aryl group
and an isosteric sulfamide linker were designed as well (compounds
18-35) (Table 3). Their inhibition study confirmed that the first types
of molecules (compounds 9, 10) are competitive inhibitors against

Table 2

CMP-sialic acid analog inhibitors of sialyltransferases.

cytidine conjugates against Campylobacter jejuni sialyltransferase
(Cst06), whereas the last two types could only inhibit the enzyme
non-competitively. These results indicated that increasing hydrophobicity of a molecule may improve its binding. As they pointed out, the
better way to improve the bioavailability of a sialyltransferase inhibitor
is not to eliminate the charge, but rather to temporary mask the charge
and make a pro-inhibitor [28].

2.3. Cytidine analogs
Schmidt and co-workers proposed a transition-state model of
SN1-type mechanism of sialyl transfer for designing inhibitors that exhibits particularly high binding affinities to α2,6-sialyltransferases
[29]. They found that replacement of the neuraminyl residue by a
wide range of aryl rings or hetaryl methylphosphonate residues
(thiazole, benzothiazole, benzoxazole, benzothiophene and thiophene)
in transition-state analogs of CMP-Neu5Ac led to readily accessible and
potent inhibitors of α2,6- and α2,3-sialyltransferases (compounds 3647) [29,30]. In addition, based on the structures of cytidine and adenosines, Lenselot's group synthesized some inhibitors of STs by replacing
the 5'-alcohol with triazole derivatives (compounds 48-51) [31].
They found that 5'-triazole adenosines were less efficient inhibitors of
α2,3-sialyltransferase than their cytidine analogs, which suggested the
hydrophobic functionality and the cytidine group are clearly required
for the improved binding. Later, Satomi and co-workers synthesized
several transition state mimics by applying regio- and stereospecific
rearrangement initiated by monohydrolysis of a symmetric diester
(compounds 52-57 in Table 3) [32]. However, there is no sialyltransferases
inhibiting activity reported yet.
Polysialic acid is a homopolymer of α2,8-linked sialic acid attached
to the neural cell adhesion molecule (NCAM) and plays an essential
role in neuronal development [33]. Its biosynthesis is regulated by
polysialyltransferases. It has been found that polysialic acid is also
aberrantly re-expressed on the surface of many tumors, where it plays
a key role in disease progression and metastasis [34]. Therefore,
polysialyltransferases have been also considered as an attractive
anti-cancer drug target. Fukuda's group synthesized CMP-sialic acid
analogs 5-methyl CMP (58) and 2'-O-methyl CMP (59) (Table 3) as
polysialyltransferase inhibitors [35]. They found that 2'-O-methyl CMP
(59) and moderately by 5-methyl CMP (58) strongly inhibited ST8SiaIV as well as ST8Sia-lI and ST8Sia-Ill. Moreover, 5-methyl CMP (58),
2'-O-methyl CMP (59), and CMP (60) could reduce the polysialic acid
expression on the cell surface. In addition, they found that 5-methyl
CMP (58) and 2'-O-methyl CMP (59) inhibited ST3Gal-llI, ST3Gal-lV
and ST6Gal-I in different degrees as well. Recently, this group and
their collaborators further confirmed that the pharmacological inhibition of polysialyltransferase ST8SiaII modulates tumor cell migration
[36]. These results indicated that analogs 5-methyl CMP (58) and
2'-O-methyl CMP (59) can be used to preferentially inhibit
polysialyltransferases and their further in vivo studies for anticancer
drug development are much expected.

2.4. Oligosaccharide derivatives
Considerable effort has also been dedicated to the design and synthesis of inhibitors of sialylation processing enzymes focusing on the receptor specificity by using modified lactose and lactosamine [37-39].
Through the studies of structure-effective relationship, Wlasichuk and
co-workers reported that the C-6' hydroxyl and acetamido group of
LacNAc are essential for sialylation by rat liver α2,6-sialyltransferase
[37] . Methylation of the C-6 and C-2' hydroxyls of LacNAc had only a
minimal effect on α2,3-sialyltransferase [39], but there was no inhibition of α2,3-sialyltransferase when the C-2' hydroxyl of LacNAc was
epimerized [38]. In addition, fluorine-containing mucin core 2 oligosaccharide analogs in which the fluorine atom located at different positions
of galactose residue were synthesized in a convergent way for probing

carbohydrate-enzyme interaction and carbohydrate-selectin interaction. As a result, these compounds (61-65 in Table 4) showed inhibitory
activities against sialyltransferases, which indicated that the fluorine
modification dramatically decreased the donor reactivity due to
electron-withdrawing effect [40].

2.5. Aromatic compounds
Natural products are great resources for drug discovery. Polyphenol
natural products possess radical scavenging and anti-oxidative properties and exhibit many biological activities, such as anti-inflammatory,
antimicrobial, anti-cancer, and chemopreventive activities. In addition,
they show to inhibit cell adhesion. Therefore, aromatic natural products
were screened as sialyltransferase inhibitors related to anticancer and
anti-inflammatory therapy. Gallic acid (66, GA), gallate esters (67) and
( —)-epigallocatechin gallate (68, EGCG) were reported to inhibit
α2,3-(N)-sialyltransferase in the low micromolar range (Table 5) [41].
In addition, Cory's group synthesized 5 negatively charged sulfonic
acid analogs of natural products (69-73) (Table 5), which were tested
to inhibit the sialyltransferase by the sialyltransferase assay based on
transferring of F1TCNeuAc from CMP-FITCNeuAc to N-linked (mediated
by ST6Gal I and ST3Gal III) and O-linked (mediated by ST3Gal
I) glycans of asialo-fetuin [42]. As a result, compound 73 showed strong
inhibition against α2,3-sialyltransferases (ST3Gal Ill, IC50 = 3.1 μM;
ST3Gal I,IC5O = 14.1 μM), and ct2,6-sialyltransferase (ST6Gal I,IC5O =
10.8 μM), while compound 71 exhibited a more than 250-fold
(IC5O =1.7 μM) higher potency for ST3Gal III than for all the other
sialyltransferases. Future in vivo studies for anticancer drug
development are much expected.

2.6. Flavonoids
Nature product flavonoids have various bioactivities such as
antiviral and antioxidation activity and are explored as candidates for
drug development. Flavonoid derivatives (74-81) were tested as
sialyltransferase inhibitors on β-galactoside α2,6-sialyltransferase I
(ST6Gal I) and β-galactoside α2,3-sialyltransferase [43,44]. Three
characteristic features of flavonoids were determined by structure-inhibitory activity relationships. First, a double bond between C2-C3 linkages is required for the activity. Second, increasing hydrophilic
properties on the B-ring markedly augmented the inhibitory effect.
Third, a hydrophobic functional group introduced on the hydroxyl
groups of the A-ring enhanced the inhibitory activity (Table 6). These
results indicated that flavonoids could inhibit sialyltransferases and
their further in vivo studies for anticancer drug development are much
expected.

2.7. Lithocholic acid analogs
As described above, ST inhibitors with a structural mimetic of
transition-state analogs, bisubstrate analogs, donor analogs, and accep
tor analogs were developed designed on CMP-Neu5Ac or acceptor
oligosaccharides. Although these compounds were demonstrated to ef
fectively inhibit sialyltransferases. However, these inhibitors all may
have poor permeability across cell membranes and their bioavailability
may be lower and thus their clinical applications are relatively limited.
So far, few ST inhibitors with a cell-permeable property have been reported [21,28]. Chang's group designed and synthesized 16 lithocholic
acid analogs (82-100) (Table 7), which employed a steroidal moiety
to improve their uptake, and demonstrated to be noncompetitive inhibitors of ct2,3-sialyltransferase (ct2,3-ST) in the presence of CMP-Neu5Ac
[45]. Among these compounds, Lith-O-Asp (82) suppressed cancer cell
metastasis likely by inhibiting FAK/paxillin signaling and expressing
anti-angiogenesis factors [46]. Further, this group found a novel
sialyltransferase inhibitor AL-10 (101) from the lead compound
lithocholic acid analogs with potent anti-cancer effect [47]. Compound

Table 3

Cytidine analog inhibitors of sialyltransferases.

Table 3 (continued)

59

Inhibition of enzyme: ST8Sia II, ST3Gal-III, ST6Gal-I,
ST3Gal-IV, ST8Sia-III, ST8Sia-IV, polyST (Refs: [35,36])

101 was cell-permeable and effectively attenuates total sialylation on
cell surface. Interestingly, this inhibitor compound had no cytotoxicity
but inhibited adhesion, migration, actin polymerization and invasion
of α2,3-ST-overexpressing A549 and CL1.5 human lung cells. Inhibition
of adhesion and migration by compound 101 is associated with reduced
sialylation of various integrin molecules. Further, compound 101 significantly suppresses experimental lung metastasis in vivo without affecting the liver and kidney function of experimental animals as determined
by serum biochemical assays. Taken together, compound 101 is the first
ST inhibitor, which exhibits potent anti-metastatic activity in vivo and
thus is worthy for further preclinical testing as a novel drug for cancer
treatment.

Inhibition of enzyme: ST8Sia II, ST3Gal-III, ST6Gal-I,
ST3Gal-IV, ST8Sia-III, ST8Sia-IV, polyST (Refs: [35,36])

2.8. Others
Some other natural products (Table 8) were also found to act as
inhibitors of sialyltransferases, such as three known spirocyclic drimanes
(102-104) isolated from the culture broth of the fungus Stachybotrys
cylindrospora possessed inhibitory activity sialyltransferase but not
β1,4-galactosyltransferase [48]. In addition, polyoxometalates (PMs) as
discrete metal-oxide cluster anions, specified by high solubility in water
and highly structure-selective activity, were investigated with an interest
as a candidate of inorganic drug. Akira's group reported some types of
PMs, molybdate tungstate and vanadate having the ability to inhibit specific STs [49].

Table 4

Oligosaccharide inhibitors of sialyltransferases.

Table 5

Aromatic compound inhibitors of sialyltransferases.

3. Summary and future perspective

Sialyltransferases as glycosyltransferases control the linkage
and level of cell surface sialic acids and play key roles in many biological
processes of human health and disease, such as inflammation, cancer
and infection diseases. Therefore, STs are potential drug targets in a
range of therapeutic areas. Over the past decades, several potent
sialyltransferase inhibitors have been designed based on the enzyme
donor analog or receptor analog theory and assumptions of the transition state in the active site, which exhibit inhibition constants in
the low concentration range. In addition, natural products as noncompetitive sialyltransferase inhibitors were found with potent inhibitory activities. Overall, eight types of sialyltransferase inhibitors were
summarized in this review, and sialic acid analogs, CMP-sialic acid

analogs and cytidine analogs are the main inhibitors of
sialyltransferases, which could be recognized by the enzyme. However,
most nucleotide analogs have poor membrane permeability and have
less chance to be developed as drug candidates. Therefore, further research such as modifying with acetyl or other group to improve the
membrane permeability of nucleotide analogs may facilitate the high
chance for drug development. In addition, site specific sialyltransferase
inhibition should be explored in order to avoid disrupting the physiologically important sialylation and thus for therapeutic efficiency. On the
other hand, natural products, such as lithocholic acid analogs, flavonoids
and aromatic analogs were found as sialyltransferase inhibitors. These
compounds will serve as lead compounds for sialyltransferase-targeting
drug development too. The search for potent inhibitors of
sialyltransferases is still challenging because rational drug design are

Table 6

Flavonoid inhibitors of sialyltransferases.

still impossible so far. This is explained at least in part by the complexity
and flexibility of the macromolecule and this should be considered in
structure-based inhibitor design for sialyltransferases. Nevertheless, the
studies so far have unlocked the potential for inhibition of
sialyltransferases as an exciting and desperately needed therapeutic opportunity for diseases such as cancer. There is no doubt that continuing

basic and preclinical researches related to sialyltransferase inhibition
will provide promising outcome for human health.
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